anti basigin Search Results


90
R&D Systems rat anti mouse emmprin
Figure 1: <t>EMMPRIN</t> structure and peptide design, and specificity of 161-Ab: (A) Partial
Rat Anti Mouse Emmprin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Mouse+EMMPRIN%2FCD147+Antibody/10__1080_slash_2162402x__2015__1078056-156-9-13
Average 90 stars, based on 1 article reviews
rat anti mouse emmprin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
Proteintech anti cd147
Figure 1: <t>EMMPRIN</t> structure and peptide design, and specificity of 161-Ab: (A) Partial
Anti Cd147, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/CD147+Antibody/pmc10873344-280-34-35
Average 94 stars, based on 1 article reviews
anti cd147 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology emmprin
Figure 4. A, Influence of <t>the</t> <t>MMP</t> inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced <t>EMMPRIN</t> release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).
Emmprin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/EMMPRIN+Antibody/10__1161_slash_01__atv__0000142806__59283__11-189-13-18
Average 93 stars, based on 1 article reviews
emmprin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
R&D Systems cd147
Figure 4. A, Influence of <t>the</t> <t>MMP</t> inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced <t>EMMPRIN</t> release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).
Cd147, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Human+EMMPRIN%2FCD147+Antibody/pmc04694784-145-6-8
Average 92 stars, based on 1 article reviews
cd147 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Miltenyi Biotec anti tra 1 85
Figure 4. A, Influence of <t>the</t> <t>MMP</t> inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced <t>EMMPRIN</t> release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).
Anti Tra 1 85, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/TRA-1-85+(CD147)+Antibody%2C+anti-human%2C+REAfinity/pmc08654291-144-20-22
Average 93 stars, based on 1 article reviews
anti tra 1 85 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems bsg
Figure 4. A, Influence of <t>the</t> <t>MMP</t> inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced <t>EMMPRIN</t> release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).
Bsg, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Human+EMMPRIN%2FCD147+Antibody/10__1161_slash_atvbaha__115__306686-478-7-10
Average 94 stars, based on 1 article reviews
bsg - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
R&D Systems goat anti mouse cd147 antibody
Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse <t>CD147</t> allele (flanking primers BSGC and BSGD)
Goat Anti Mouse Cd147 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Mouse+EMMPRIN%2FCD147+Biotinylated+Antibody/pmc09187929-43-19-23
Average 92 stars, based on 1 article reviews
goat anti mouse cd147 antibody - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

92
R&D Systems human emmprin cd147 ab
Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse <t>CD147</t> allele (flanking primers BSGC and BSGD)
Human Emmprin Cd147 Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Human+EMMPRIN%2FCD147+Antibody/pm32473077-32-21-28
Average 92 stars, based on 1 article reviews
human emmprin cd147 ab - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

90
R&D Systems biotinylated antibodies
Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse <t>CD147</t> allele (flanking primers BSGC and BSGD)
Biotinylated Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Human+EMMPRIN%2FCD147+Biotinylated+Antibody/pmc06685952-185-24-30
Average 90 stars, based on 1 article reviews
biotinylated antibodies - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
R&D Systems goat polyclonal antibody against recombinant human emmprin
FIG. 1. <t>EMMPRIN</t> protein localization in cycling human eutopic uter- ine endometrium. Tissue sections were probed with human anti- EMMPRIN antibody or nonspecific IgG. The stages of the menstrual cycle shown are: A, early menses; control, nonspecific IgG; B–G, probed with anti-EMMPRIN antibody; B, early menses (inset, 40); C, early proliferative (inset, 40); D, midproliferative (20); E, early secretory (inset luminal epithelium, 40); F, midsecretory; and G, late secretory (inset luminal epithelium; 40). Unless noted, all pictures were taken at 20 magnification. Arrowheads denote EMMPRIN localization to lu- minal epithelial cells. s, Stroma; l, uterine lumen; g, gland.
Goat Polyclonal Antibody Against Recombinant Human Emmprin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/Human+EMMPRIN%2FCD147+Antibody/pm16522689-81-7-14
Average 93 stars, based on 1 article reviews
goat polyclonal antibody against recombinant human emmprin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Novus Biologicals rat anti emmprin
FIG. 1. <t>EMMPRIN</t> protein localization in cycling human eutopic uter- ine endometrium. Tissue sections were probed with human anti- EMMPRIN antibody or nonspecific IgG. The stages of the menstrual cycle shown are: A, early menses; control, nonspecific IgG; B–G, probed with anti-EMMPRIN antibody; B, early menses (inset, 40); C, early proliferative (inset, 40); D, midproliferative (20); E, early secretory (inset luminal epithelium, 40); F, midsecretory; and G, late secretory (inset luminal epithelium; 40). Unless noted, all pictures were taken at 20 magnification. Arrowheads denote EMMPRIN localization to lu- minal epithelial cells. s, Stroma; l, uterine lumen; g, gland.
Rat Anti Emmprin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+basigin/EMMPRIN%2FCD147+Antibody+(OX114)+-+BSA+Free/pmc13753455-350-15-18
Average 92 stars, based on 1 article reviews
rat anti emmprin - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

Image Search Results


Figure 1: EMMPRIN structure and peptide design, and specificity of 161-Ab: (A) Partial

Journal: OncoImmunology

Article Title: An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression

doi: 10.1080/2162402x.2015.1078056

Figure Lengend Snippet: Figure 1: EMMPRIN structure and peptide design, and specificity of 161-Ab: (A) Partial

Article Snippet: One strip was probed with the 1:1,000 diluted commercial rat anti-mouse EMMPRIN (MAB772, R&D systems) and then with the 1:5,000 diluted HRP-conjugated goat anti-rat IgG (112-035- D ow nl oa de d by [ U ni ve rs ity o f R eg in a] a t 0 6: 58 2 4 Fe br ua ry 2 01 6 062, Jackson) and served as positive control (P.C).

Techniques:

Figure 4. A, Influence of the MMP inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced EMMPRIN release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells

doi: 10.1161/01.atv.0000142806.59283.11

Figure Lengend Snippet: Figure 4. A, Influence of the MMP inhibitor GM6001 (GM, 15 mol/L and 25 mol/L) on the basal and oxLDL-induced EMMPRIN release by HCA-SMC. EMMPRIN concentrations in supernatants were mea- sured by fluorescence immunoassay and referred to the DNA content in the corresponding wells. MeanSEM, expressed as relative EMMPRIN release compared with controls: n6, P0.05, P0.001 vs control, and ***P0.001 vs oxLDL 50 g/mL. B, Western blot analysis (nonreducing conditions) of EMMPRIN expres- sion in cell lysates (C) and corresponding supernatants (S) of HCA- SMC, incubated for 48 hours with Con., medium with 0.1% FCS; GM, GM6001 15 mol/L; ox50GM, oxLDL 50 g/mLGM6001 15 mol/L; and ox50, oxLDL 50 g/mL. C, Western blot analysis (reducing conditions, EMMPRIN antibody against the extracellular domain) of EMMPRIN, isolated from HCA-SMC supernatant (S) or cell lysate (C) by anion exchange and immunoaffinity chromatography. Isolated purified EMMPRIN from cell lysate was incubated for 2 hours with recombinant human MMP-1 or MMP-2; thereafter, isolated EMMPRIN from cell lysate and HCA-SMC supernatant was deglyco- sylated with N-Glycosidase F (N-Glyc.).

Article Snippet: For detection of MMP-associated EMMPRIN cleavage an additional antibody against the C-terminus of EMMPRIN was used (0.2 μg/mL; Santa Cruz).

Techniques: Control, Western Blot, Incubation, Isolation, Chromatography, Recombinant

Figure 6. A, MMP-1, MMP-2, and MMP-9 release by HCA-SMC after 48 hours incubation with EMMPRIN, isolated from super- natants of human monocyte-derived macrophages. MMP con- centrations were measured with immunoassays and referred to the corresponding DNA content. MeanSEM (n3), relative MMP release compared with controls: **P0.01 vs control. B, Zymography of HCA-SMC supernatants after 48 hours incuba- tion with isolated EMMPRIN. 1 indicates control, and 2, 20 ng/mL EMMPRIN, isolated from macrophage supernatants.

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells

doi: 10.1161/01.atv.0000142806.59283.11

Figure Lengend Snippet: Figure 6. A, MMP-1, MMP-2, and MMP-9 release by HCA-SMC after 48 hours incubation with EMMPRIN, isolated from super- natants of human monocyte-derived macrophages. MMP con- centrations were measured with immunoassays and referred to the corresponding DNA content. MeanSEM (n3), relative MMP release compared with controls: **P0.01 vs control. B, Zymography of HCA-SMC supernatants after 48 hours incuba- tion with isolated EMMPRIN. 1 indicates control, and 2, 20 ng/mL EMMPRIN, isolated from macrophage supernatants.

Article Snippet: For detection of MMP-associated EMMPRIN cleavage an additional antibody against the C-terminus of EMMPRIN was used (0.2 μg/mL; Santa Cruz).

Techniques: Incubation, Isolation, Derivative Assay, Control, Zymography

Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse CD147 allele (flanking primers BSGC and BSGD)

Journal: Cell & Bioscience

Article Title: Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection

doi: 10.1186/s13578-022-00822-6

Figure Lengend Snippet: Schematic representation of genotyping primers used to confirm hCD147KI expression. A combination of 4 primers was used to screen mice (internal primers hCD147A and hCD147B) and confirm proper integration into the mouse CD147 allele (flanking primers BSGC and BSGD)

Article Snippet: To stain mouse CD147 (mCD147), polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705–035-003 [HRP]; 1:500) was used against primary goat anti-mouse CD147 antibody (R&D Systems; BAF772; 1:100).

Techniques: Expressing

H&E and IHC of human CD147 in hCD147KI het -NSG mice. Human CD147 was stained (HIM6; 1:500) in the ( A ) lung, ( B ) liver, ( C ) intestine, ( D ) heart, ( E ) brain, ( F ) spleen, ( G ) kidney, ( H ) testis, and ( I ) trachea in WT-NSG (top) and hCD147KI het -NSG (bottom) mice. Images were taken using an Olympus Inverted Light Microscope. Scale bar represents 100 µm

Journal: Cell & Bioscience

Article Title: Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection

doi: 10.1186/s13578-022-00822-6

Figure Lengend Snippet: H&E and IHC of human CD147 in hCD147KI het -NSG mice. Human CD147 was stained (HIM6; 1:500) in the ( A ) lung, ( B ) liver, ( C ) intestine, ( D ) heart, ( E ) brain, ( F ) spleen, ( G ) kidney, ( H ) testis, and ( I ) trachea in WT-NSG (top) and hCD147KI het -NSG (bottom) mice. Images were taken using an Olympus Inverted Light Microscope. Scale bar represents 100 µm

Article Snippet: To stain mouse CD147 (mCD147), polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705–035-003 [HRP]; 1:500) was used against primary goat anti-mouse CD147 antibody (R&D Systems; BAF772; 1:100).

Techniques: Staining, Light Microscopy

Flow cytometric analysis reveals proper dual-expression of both mCD147 and hCD147 in PBMCs and various organs. Representative contour plots of CD147 expression on WT-NSG (top) and hCD147KI het -NSG (bottom) cells from ( A ) PBMCs, ( B ) lung, ( C ) liver, and ( D ) spleen using antibodies targeting either mouse CD147 protein, human CD147 protein, or a combination of both antibodies (far right). Relative percentages are listed, and significant shifts highlighted in red. Gating was determined based on donkey anti-goat/mouse isotype IgG antibody background staining

Journal: Cell & Bioscience

Article Title: Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection

doi: 10.1186/s13578-022-00822-6

Figure Lengend Snippet: Flow cytometric analysis reveals proper dual-expression of both mCD147 and hCD147 in PBMCs and various organs. Representative contour plots of CD147 expression on WT-NSG (top) and hCD147KI het -NSG (bottom) cells from ( A ) PBMCs, ( B ) lung, ( C ) liver, and ( D ) spleen using antibodies targeting either mouse CD147 protein, human CD147 protein, or a combination of both antibodies (far right). Relative percentages are listed, and significant shifts highlighted in red. Gating was determined based on donkey anti-goat/mouse isotype IgG antibody background staining

Article Snippet: To stain mouse CD147 (mCD147), polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705–035-003 [HRP]; 1:500) was used against primary goat anti-mouse CD147 antibody (R&D Systems; BAF772; 1:100).

Techniques: Expressing, Staining

Diagram of proposed working hypothesis of CD147 in SARS-CoV-2 infection. (1) SARS-CoV-2 virions infect human cells via the canonical pathway where host Angiotensin-converting Enzyme 2 (ACE2) receptors bind to viral spike proteins (red) and facilitate viral entry and infection. (2) CD147 proteins, via binding to surface binding partners (e.g., E-selectin), facilitate cell–cell adhesion, membrane fusion, and intercellular transfer of SARS-CoV-2 virions. (3) Erythrocytes and platelets which strongly express CD147, bind SARS-CoV-2 virions, and increase thrombosis risk and other clinical manifestations of COVID-19

Journal: Cell & Bioscience

Article Title: Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection

doi: 10.1186/s13578-022-00822-6

Figure Lengend Snippet: Diagram of proposed working hypothesis of CD147 in SARS-CoV-2 infection. (1) SARS-CoV-2 virions infect human cells via the canonical pathway where host Angiotensin-converting Enzyme 2 (ACE2) receptors bind to viral spike proteins (red) and facilitate viral entry and infection. (2) CD147 proteins, via binding to surface binding partners (e.g., E-selectin), facilitate cell–cell adhesion, membrane fusion, and intercellular transfer of SARS-CoV-2 virions. (3) Erythrocytes and platelets which strongly express CD147, bind SARS-CoV-2 virions, and increase thrombosis risk and other clinical manifestations of COVID-19

Article Snippet: To stain mouse CD147 (mCD147), polyclonal donkey anti-goat IgG secondary (Jackson ImmunoResearch; 705–035-003 [HRP]; 1:500) was used against primary goat anti-mouse CD147 antibody (R&D Systems; BAF772; 1:100).

Techniques: Infection, Binding Assay, Membrane

FIG. 1. EMMPRIN protein localization in cycling human eutopic uter- ine endometrium. Tissue sections were probed with human anti- EMMPRIN antibody or nonspecific IgG. The stages of the menstrual cycle shown are: A, early menses; control, nonspecific IgG; B–G, probed with anti-EMMPRIN antibody; B, early menses (inset, 40); C, early proliferative (inset, 40); D, midproliferative (20); E, early secretory (inset luminal epithelium, 40); F, midsecretory; and G, late secretory (inset luminal epithelium; 40). Unless noted, all pictures were taken at 20 magnification. Arrowheads denote EMMPRIN localization to lu- minal epithelial cells. s, Stroma; l, uterine lumen; g, gland.

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

doi: 10.1210/jc.2005-0601

Figure Lengend Snippet: FIG. 1. EMMPRIN protein localization in cycling human eutopic uter- ine endometrium. Tissue sections were probed with human anti- EMMPRIN antibody or nonspecific IgG. The stages of the menstrual cycle shown are: A, early menses; control, nonspecific IgG; B–G, probed with anti-EMMPRIN antibody; B, early menses (inset, 40); C, early proliferative (inset, 40); D, midproliferative (20); E, early secretory (inset luminal epithelium, 40); F, midsecretory; and G, late secretory (inset luminal epithelium; 40). Unless noted, all pictures were taken at 20 magnification. Arrowheads denote EMMPRIN localization to lu- minal epithelial cells. s, Stroma; l, uterine lumen; g, gland.

Article Snippet: Slides were then incubated with 2 g/ml goat polyclonal antibody against recombinant human EMMPRIN (R&D Systems, Inc.) in 1% BSA in PBS at 4 C overnight.

Techniques: Control

FIG. 3. Changes in MMP-1, -2, and -3 and EMMPRIN mRNA levels in response to treatment with EMMPRIN or IL-1. RNA was collected after treatment of HUF cells with either IL-1 or EMMPRIN at the indicated concentrations for 24 h. Fold changes in mRNA levels were quantitated by TaqMan PCR normalized to GAPDH and calibrated to control levels. A, Changes in MMP-1 and -2 mRNA levels; B, changes in MMP-3 mRNA levels; C, changes in EMMPRIN mRNA levels (n 3; P 0.05). Statistical significance was calculated from normalized data and is indicated by different letters above treatments.

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

doi: 10.1210/jc.2005-0601

Figure Lengend Snippet: FIG. 3. Changes in MMP-1, -2, and -3 and EMMPRIN mRNA levels in response to treatment with EMMPRIN or IL-1. RNA was collected after treatment of HUF cells with either IL-1 or EMMPRIN at the indicated concentrations for 24 h. Fold changes in mRNA levels were quantitated by TaqMan PCR normalized to GAPDH and calibrated to control levels. A, Changes in MMP-1 and -2 mRNA levels; B, changes in MMP-3 mRNA levels; C, changes in EMMPRIN mRNA levels (n 3; P 0.05). Statistical significance was calculated from normalized data and is indicated by different letters above treatments.

Article Snippet: Slides were then incubated with 2 g/ml goat polyclonal antibody against recombinant human EMMPRIN (R&D Systems, Inc.) in 1% BSA in PBS at 4 C overnight.

Techniques: Control

FIG. 2. Changes in EMMPRIN mRNA levels in uterine endometrium throughout the menstrual cycle. Biopsies of eutopic endometrium from throughout the menstrual cycle were analyzed by real-time PCR for EMMPRIN mRNA expression. EMMPRIN mRNA levels were normalized to GAPDH and calibrated to the late secretory stage to determine relative expression levels. Bar A indicates significant dif- ferences between proliferative and secretory stages, bar B indicates significant differences between mid- and late secretory stages, and bar C indicates significant differences between early and late secre- tory stages (n 4 for each cycle stage; P 0.05).

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

doi: 10.1210/jc.2005-0601

Figure Lengend Snippet: FIG. 2. Changes in EMMPRIN mRNA levels in uterine endometrium throughout the menstrual cycle. Biopsies of eutopic endometrium from throughout the menstrual cycle were analyzed by real-time PCR for EMMPRIN mRNA expression. EMMPRIN mRNA levels were normalized to GAPDH and calibrated to the late secretory stage to determine relative expression levels. Bar A indicates significant dif- ferences between proliferative and secretory stages, bar B indicates significant differences between mid- and late secretory stages, and bar C indicates significant differences between early and late secre- tory stages (n 4 for each cycle stage; P 0.05).

Article Snippet: Slides were then incubated with 2 g/ml goat polyclonal antibody against recombinant human EMMPRIN (R&D Systems, Inc.) in 1% BSA in PBS at 4 C overnight.

Techniques: Real-time Polymerase Chain Reaction, Expressing

FIG. 4. Changes in MMP-1, -2, and-3 protein secretion in response to EMMPRIN or IL-1. A, Immunoblots of conditioned medium samples collected from treated HUF cells. Membranes were probed with spe- cific antibodies and detected with appropriate secondary antibodies. Lane 1, Control IL-1; lane 2, 10 ng/ml IL-1; lane 3, control EMMPRIN; lane 4, 0.5 g/ml EMMPRIN; lane 5, 1 g/ml EMMPRIN (n 3). Treatments of cells with IL-1 and EMMPRIN were con- ducted in separate experiments; therefore, two sets of untreated con- trol cells are shown. B, Densitometric analysis of immunoblots was normalized to the values for untreated control medium samples. Bars indicate the SE of treatments.

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

doi: 10.1210/jc.2005-0601

Figure Lengend Snippet: FIG. 4. Changes in MMP-1, -2, and-3 protein secretion in response to EMMPRIN or IL-1. A, Immunoblots of conditioned medium samples collected from treated HUF cells. Membranes were probed with spe- cific antibodies and detected with appropriate secondary antibodies. Lane 1, Control IL-1; lane 2, 10 ng/ml IL-1; lane 3, control EMMPRIN; lane 4, 0.5 g/ml EMMPRIN; lane 5, 1 g/ml EMMPRIN (n 3). Treatments of cells with IL-1 and EMMPRIN were con- ducted in separate experiments; therefore, two sets of untreated con- trol cells are shown. B, Densitometric analysis of immunoblots was normalized to the values for untreated control medium samples. Bars indicate the SE of treatments.

Article Snippet: Slides were then incubated with 2 g/ml goat polyclonal antibody against recombinant human EMMPRIN (R&D Systems, Inc.) in 1% BSA in PBS at 4 C overnight.

Techniques: Western Blot, Control

FIG. 5. EMMPRIN protein and mRNA expression in ectopic human endometrium (endometriotic lesions). A, Representative immunohis- tochemical analysis of EMMPRIN protein localization in lesions from three patients. Patient 1, a, Control, nonspecific IgG; c, anti- EMMPRIN antibody; patient 2, b, control, nonspecific IgG; d, anti- EMMPRIN antibody; e and f, patient 3, anti-EMMPRIN antibody. The arrowhead denotes EMMPRIN expression in peritoneal mesothe- lial cells. Magnification of photos: a and c, 20; b and d, 40; e, 20; and f, 40. ms, Mesothelial stroma; ge, uterine glandular epithelium; us, uterine stroma. B, Real-time PCR analysis of matched eutopic and ectopic endometria for EMMPRIN mRNA levels. Samples were nor- malized to endogenous control GAPDH mRNA levels and calibrated to eutopic endometrium of disease-free controls at the same stage of the menstrual cycle. The experimental unit is indicated above each sample.

Journal: The Journal of clinical endocrinology and metabolism

Article Title: Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

doi: 10.1210/jc.2005-0601

Figure Lengend Snippet: FIG. 5. EMMPRIN protein and mRNA expression in ectopic human endometrium (endometriotic lesions). A, Representative immunohis- tochemical analysis of EMMPRIN protein localization in lesions from three patients. Patient 1, a, Control, nonspecific IgG; c, anti- EMMPRIN antibody; patient 2, b, control, nonspecific IgG; d, anti- EMMPRIN antibody; e and f, patient 3, anti-EMMPRIN antibody. The arrowhead denotes EMMPRIN expression in peritoneal mesothe- lial cells. Magnification of photos: a and c, 20; b and d, 40; e, 20; and f, 40. ms, Mesothelial stroma; ge, uterine glandular epithelium; us, uterine stroma. B, Real-time PCR analysis of matched eutopic and ectopic endometria for EMMPRIN mRNA levels. Samples were nor- malized to endogenous control GAPDH mRNA levels and calibrated to eutopic endometrium of disease-free controls at the same stage of the menstrual cycle. The experimental unit is indicated above each sample.

Article Snippet: Slides were then incubated with 2 g/ml goat polyclonal antibody against recombinant human EMMPRIN (R&D Systems, Inc.) in 1% BSA in PBS at 4 C overnight.

Techniques: Expressing, Control, Real-time Polymerase Chain Reaction